Oxygenta Pharmaceutical Ltd

₹ 63.7 3.08%

31 Oct - close price

About

Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.

Key Points

Products:^[1]
Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti
cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.

Website BSE

Market Cap ₹ 236 Cr.
Current Price ₹ 63.7
High / Low ₹ 134 / 53.6
Stock P/E
Book Value ₹ -6.77
Dividend Yield 0.00 %
ROCE -24.9 %
ROE %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter
Debtor days have improved from 68.2 to 17.0 days.
Company's median sales growth is 27.9% of last 10 years

Cons

Company has low interest coverage ratio.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
	8.89	6.06	7.85	8.19	6.86	13.08	9.15	10.55	12.62	14.01	33.21	49.47	15.13
	9.93	7.56	10.18	10.44	10.50	15.06	11.63	12.17	14.40	16.18	37.57	51.15	21.96
Operating Profit	-1.04	-1.50	-2.33	-2.25	-3.64	-1.98	-2.48	-1.62	-1.78	-2.17	-4.36	-1.68	-6.83
OPM %	-11.70%	-24.75%	-29.68%	-27.47%	-53.06%	-15.14%	-27.10%	-15.36%	-14.10%	-15.49%	-13.13%	-3.40%	-45.14%
	0.00	-0.34	-0.32	-0.05	-0.13	-0.03	-0.02	0.26	0.02	0.75	0.49	-0.22	0.16
Interest	0.25	0.10	0.20	0.94	0.29	0.34	0.36	0.59	0.41	0.69	0.39	2.13	0.63
Depreciation	0.40	0.40	0.40	0.85	0.50	0.83	0.69	0.64	0.65	0.66	0.71	-0.23	0.85
Profit before tax	-1.69	-2.34	-3.25	-4.09	-4.56	-3.18	-3.55	-2.59	-2.82	-2.77	-4.97	-3.80	-8.15
Tax %	0.00%	0.00%	0.00%	4.89%	0.00%	-0.63%	6.48%	-409.27%	-51.42%	2.89%	-20.72%	-43.42%	-25.03%
	-1.69	-2.34	-3.25	-4.29	-4.56	-3.16	-3.78	8.02	-1.36	-2.85	-3.93	-2.15	-6.11
EPS in Rs	-1.19	-1.65	-2.29	-3.02	-1.36	-0.94	-1.13	2.40	-0.38	-0.80	-1.06	-0.58	-1.65
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	2	6	12	8	13	21	14	52	61	31	40	109	112
	6	10	16	13	17	23	22	48	59	38	49	119	127
Operating Profit	-3	-4	-4	-5	-4	-2	-8	4	1	-7	-10	-10	-15
OPM %	-142%	-67%	-34%	-59%	-31%	-10%	-57%	7%	2%	-23%	-24%	-9%	-13%
	0	0	0	1	1	0	4	2	1	-1	0	1	1
Interest	0	0	1	1	1	1	1	2	1	1	2	2	4
Depreciation	1	3	1	1	1	1	1	1	2	2	3	1	2
Profit before tax	-4	-7	-6	-6	-4	-3	-6	3	-0	-11	-14	-12	-20
Tax %	5%	-11%	0%	2%	1%	-7%	-3%	7%	24%	2%	-75%	-16%
	-4	-6	-6	-6	-5	-3	-6	3	-1	-12	-3	-10	-15
EPS in Rs	-4.21	-5.99	-5.39	-5.70	-4.44	-3.19	-5.68	2.87	-0.43	-8.15	-1.04	-2.62	-4.09
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	33%
5 Years:	51%
3 Years:	22%
TTM:	146%

Compounded Profit Growth
10 Years:	-7%
5 Years:	1%
3 Years:	%
TTM:	-3182%

Stock Price CAGR
10 Years:	25%
5 Years:	%
3 Years:	30%
1 Year:	-35%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Balance Sheet

Figures in Rs. Crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	10	10	10	10	10	10	10	10	14	14	33	37
Reserves	-19	-26	-32	-38	-42	-45	-51	-48	-49	-60	-54	-62
	11	15	17	19	19	22	27	48	52	68	57	62
	17	19	24	27	30	34	33	24	14	32	26	46
Total Liabilities	18	18	20	19	17	21	19	34	31	54	63	83
	16	12	13	12	12	12	11	16	20	28	29	40
CWIP	0	0	0	0	0	0	0	1	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	2	6	7	6	5	9	7	17	11	26	34	44
Total Assets	18	18	20	19	17	21	19	34	31	54	63	83

Cash Flows

Figures in Rs. Crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-3	-4	1	1	1	-8	-3	-2	-2	-2	-13	3
	-2	1	-2	-1	-0	-1	-0	-7	-5	-10	-4	-11
	4	3	1	0	-1	8	3	9	6	11	17	9
Net Cash Flow	-1	0	-0	0	-0	0	0	0	-0	-0	-0	0

Ratios

Figures in Rs. Crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	128	38	44	39	14	9	11	11	10	120	68	17
Inventory Days	33	84	41	122	57	121	100	121	56	178	149	78
Days Payable	10,165	1,800	667	599	396	203	190	137	50	362	249	113
Cash Conversion Cycle	-10,004	-1,678	-582	-439	-325	-73	-79	-5	16	-64	-32	-18
Working Capital Days	-1,576	-616	-454	-512	-438	-164	-275	-14	8	-94	-89	-184
ROCE %	-188%								-1%	-47%	-42%	-25%

Shareholding Pattern

Numbers in percentages

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
	12.34%	8.99%	26.80%	29.73%	29.73%	29.73%	33.68%	53.28%	51.12%	51.12%	57.95%	57.95%
	0.07%	0.07%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
	87.60%	90.95%	73.18%	70.24%	70.24%	70.24%	66.28%	46.69%	48.84%	48.84%	42.02%	42.01%
No. of Shareholders	9,101	8,995	8,987	8,972	9,051	10,102	9,970	10,154	10,107	10,030	10,094	10,179

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
	36.78%	36.78%	17.17%	17.17%	17.17%	12.33%	8.99%	29.73%	51.12%	57.95%
	0.10%	0.10%	0.10%	0.10%	0.10%	0.07%	0.07%	0.03%	0.03%	0.03%
	63.13%	63.13%	82.73%	82.73%	82.73%	87.60%	90.95%	70.24%	48.84%	42.01%
No. of Shareholders	8,852	8,814	8,771	8,758	8,762	9,038	8,995	10,102	10,030	10,179

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports